In person From March 18 to 20, ZoBio participated in BIO- Europe Spring in Barcelona. With over 3,700 biotechnology and pharma leaders in attendance, it’s a prime venue to establish new partnerships and explore potential business opportunities. Jan Schultz, Managing Director of Business Development, actively participated in One-on-One meetings. These meetings provided a valuable opportunity…
Fragment-Based Lead Discovery as a Powerful Approach for Identifying Novel SOS2:KRAS PPI Inhibitors
The recent publication in the Journal of Medicinal Chemistry by Mirati Therapeutics, ZoBio and Inixium nicely demonstrates the power of biophysics, structural biology and fragments to address an important…
9th RSC-BMCS Fragment-based Drug Discovery Meeting
In person ZoBio attended the 9th RSC-BMCS Fragment-based Drug Discovery meeting in Cambridge. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs. ZoBio was represented by Pim de Vink (Scientist, Assay Development and Screening) who presented poster Screening for Fragment Molecular…
Oncodesign Services Acquires ZoBio
We are excited to announce that ZoBio will join forces with Oncodesign Services (ODS), a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services with notable expertise in oncology and immuno-inflammation.
https://www.oncodesign-services.com/